RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400

Benzinga Newsdesk www.benzinga.com Positive 65.6%

Neg 0% Neu 0% Pos 65.6%

RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outperform rating and announces Price Target of $400.